Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Intra-Cellular Therapies navigates acquisition by J&J, strong Caplyta sales, and shareholder scrutiny, impacting the CNS market. Key insights and strategic implications analyzed.
Intra-Cellular Therapies' acquisition by Johnson & Johnson faces shareholder lawsuits and mixed financials, creating uncertainty despite strong Caplyta sales. This analysis explores the deal and potential strategies.
Analyzing Johnson & Johnson's $14.6B acquisition of Intra-Cellular Therapies (ITCI), focusing on Caplyta's potential, legal challenges, and JNJ's strategy.
Johnson & Johnson's acquisition of Intra-Cellular Therapies for $14.6B highlights neuroscience's importance. The deal, driven by Caplyta's growth, faces legal scrutiny.